Top 5 Health Care Stocks That Could Blast Off This Month - Allakos (NASDAQ:ALLK), BioLife Solns (NASDAQ:BLFS)Benzinga • 08/21/23
Kezar Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business UpdateBusiness Wire • 08/10/23
Kezar Life Sciences Reports First Quarter 2023 Financial Results and Provides Business UpdateBusiness Wire • 05/11/23
Kezar Life Sciences Reports Fourth Quarter and Year End 2022 Financial Results and Provides Business UpdateBusiness Wire • 03/14/23
Kezar Life Sciences to Participate in the Cowen 43rd Annual Health Care ConferenceBusiness Wire • 03/01/23
Kezar Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/04/23
Kezar Life Sciences: Mid-Term Growth Levers Heavily Discounted, Reduce To HoldSeeking Alpha • 11/16/22
Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at the American College of Rheumatology Convergence 2022Business Wire • 11/14/22
Kezar Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business UpdateBusiness Wire • 11/10/22
Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at ASN's Kidney Week 2022 Annual MeetingBusiness Wire • 11/03/22
Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American Society of Nephrology's Kidney Week 2022 Annual MeetingBusiness Wire • 10/14/22
Kezar Life Sciences Receives FDA Clearance of IND for Zetomipzomib for the Treatment of Autoimmune HepatitisBusiness Wire • 10/03/22
Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American College of Rheumatology Convergence 2022Business Wire • 09/29/22
Kezar Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business UpdateBusiness Wire • 08/11/22
Wall Street Analysts See an 82% Upside in Kezar Life Sciences, Inc. (KZR): Can the Stock Really Move This High?Zacks Investment Research • 07/18/22
Kezar Life Sciences Appoints Nick Mordwinkin as Chief Business Officer and Reports Updated Cash PositionBusiness Wire • 07/11/22
Wall Street Analysts Think Kezar Life Sciences, Inc. (KZR) Could Surge 135%: Read This Before Placing a BetZacks Investment Research • 06/30/22